251 related articles for article (PubMed ID: 34957875)
1. Addressing the obstacles of CAR T cell migration in solid tumors: wishing a heavy traffic.
Safarzadeh Kozani P; Safarzadeh Kozani P; Rahbarizadeh F
Crit Rev Biotechnol; 2022 Nov; 42(7):1079-1098. PubMed ID: 34957875
[TBL] [Abstract][Full Text] [Related]
2. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
3. Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors.
Miao L; Zhang Z; Ren Z; Tang F; Li Y
Front Immunol; 2021; 12():687822. PubMed ID: 34093592
[TBL] [Abstract][Full Text] [Related]
4. Current Challenges and Strategies for Chimeric Antigen Receptor-T-Cell Therapy for Solid Tumors.
Chen J; Jiang H
Crit Rev Immunol; 2021; 41(1):1-12. PubMed ID: 33822521
[TBL] [Abstract][Full Text] [Related]
5. The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies.
Daei Sorkhabi A; Mohamed Khosroshahi L; Sarkesh A; Mardi A; Aghebati-Maleki A; Aghebati-Maleki L; Baradaran B
Front Immunol; 2023; 14():1113882. PubMed ID: 37020537
[TBL] [Abstract][Full Text] [Related]
6. CAR-T Therapies in Solid Tumors: Opportunities and Challenges.
Guzman G; Reed MR; Bielamowicz K; Koss B; Rodriguez A
Curr Oncol Rep; 2023 May; 25(5):479-489. PubMed ID: 36853475
[TBL] [Abstract][Full Text] [Related]
7. Making CAR T Cells a Solid Option for Solid Tumors.
Schmidts A; Maus MV
Front Immunol; 2018; 9():2593. PubMed ID: 30467505
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment.
Zhang L; Pakmehr SA; Shahhosseini R; Hariri M; Fakhrioliaei A; Karkon Shayan F; Xiang W; Karkon Shayan S
Med Oncol; 2023 Dec; 41(1):8. PubMed ID: 38062315
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment.
Zhao Z; Xiao X; Saw PE; Wu W; Huang H; Chen J; Nie Y
Sci China Life Sci; 2020 Feb; 63(2):180-205. PubMed ID: 31883066
[TBL] [Abstract][Full Text] [Related]
10. Hypoxic 3D Tumor Model for Evaluating of CAR-T Cell Therapy In Vitro.
Oh JM; Shen K
Methods Mol Biol; 2024; 2748():119-134. PubMed ID: 38070112
[TBL] [Abstract][Full Text] [Related]
11. How to Test Human CAR T Cells in Solid Tumors, the Next Frontier of CAR T Cell Therapy.
Cochrane RW; Fiorentino A; Allen E; Robino RA; Quiroga J; Ferreira LMR
Methods Mol Biol; 2024; 2748():243-265. PubMed ID: 38070118
[TBL] [Abstract][Full Text] [Related]
12. Modulating tumor physical microenvironment for fueling CAR-T cell therapy.
Luo Z; Yao X; Li M; Fang D; Fei Y; Cheng Z; Xu Y; Zhu B
Adv Drug Deliv Rev; 2022 Jun; 185():114301. PubMed ID: 35439570
[TBL] [Abstract][Full Text] [Related]
13. Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice.
Xie YJ; Dougan M; Jailkhani N; Ingram J; Fang T; Kummer L; Momin N; Pishesha N; Rickelt S; Hynes RO; Ploegh H
Proc Natl Acad Sci U S A; 2019 Apr; 116(16):7624-7631. PubMed ID: 30936321
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor T cells applied to solid tumors.
Zhou Z; Tao C; Li J; Tang JC; Chan AS; Zhou Y
Front Immunol; 2022; 13():984864. PubMed ID: 36389701
[TBL] [Abstract][Full Text] [Related]
15. Solid Tumors Challenges and New Insights of CAR T Cell Engineering.
Tahmasebi S; Elahi R; Esmaeilzadeh A
Stem Cell Rev Rep; 2019 Oct; 15(5):619-636. PubMed ID: 31161552
[TBL] [Abstract][Full Text] [Related]
16. Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors.
Akbari P; Katsarou A; Daghighian R; van Mil LWHG; Huijbers EJM; Griffioen AW; van Beijnum JR
Biochim Biophys Acta Rev Cancer; 2022 May; 1877(3):188701. PubMed ID: 35202772
[TBL] [Abstract][Full Text] [Related]
17. CAR T cell therapy in solid tumors; with an extensive focus on obstacles and strategies to overcome the challenges.
Khorasani ABS; Sanaei MJ; Pourbagheri-Sigaroodi A; Ghaffari SH; Bashash D
Int Immunopharmacol; 2021 Dec; 101(Pt B):108260. PubMed ID: 34678690
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps.
Beatty GL; O'Hara M
Pharmacol Ther; 2016 Oct; 166():30-9. PubMed ID: 27373504
[TBL] [Abstract][Full Text] [Related]
19. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.
Gowrishankar K; Birtwistle L; Micklethwaite K
Mamm Genome; 2018 Dec; 29(11-12):739-756. PubMed ID: 29987406
[TBL] [Abstract][Full Text] [Related]
20. Nanoengineered CAR-T Biohybrids for Solid Tumor Immunotherapy with Microenvironment Photothermal-Remodeling Strategy.
Chen Z; Pan H; Luo Y; Yin T; Zhang B; Liao J; Wang M; Tang X; Huang G; Deng G; Zheng M; Cai L
Small; 2021 Apr; 17(14):e2007494. PubMed ID: 33711191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
